Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form

Roger B. Cohen, MD Physician

Associate Director of Clinical Research, Abramson Cancer Center
Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is a Penn Medicine employed physician.

About Dr. Roger B. Cohen

Recognized by America's Top Doctors 2011-14

Recognized by Best Doctors in America 2011-2012, 2013-2014

Recognized in Philadelphia Magazine's annual Top Docs issue,  2011 through 2016

Clinical Specialties

Specialty:

  • Medicine
    • Medical Oncology

Programs & Centers:

Board Certification:

  • Hematology, 1986
  • Internal Medicine, 1984
  • Medical Oncology, 1993

Clinical Expertise:

  • Head and Neck Cancer
  • Lung Cancer

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Harvard Medical School
Residency: Mount Sinai Medical Center
Fellowship: Mount Sinai Medical Center
Fellowship: National Cancer Institute

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National Cerulean Pharmaceuticals, Medical Advisory Board, National Eastern Cooperative Oncology Group, National Heat Biologics, National Millennium Pharmaceuticals Discovery Oncology Scientific Advisory Board, National

Hospital Affiliation

Dr. Cohen is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Bauml Joshua, Haas Andrew, Simone Charles B, Li Susan Q, Cohen Roger B, Langer Corey J, Mao Jun J: Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial. Integrative cancer therapies : 2016.

Maquilan Genevieve, Grover Surbhi, Xanthopoulos Eric, Evans Tracey L, Aggarwal Charu, Langer Corey J, Cohen Roger B, Stevenson James P, Simone Charles B, Rengan Ramesh: Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment. American journal of clinical oncology : 2016.

Sedrak Mina S, Cohen Roger B, Merchant Raina M, Schapira Marilyn M: Cancer Communication in the Social Media Age. JAMA oncology : 2016.

Ahn Peter H, Mitra Nandita, Alonso-Basanta Michelle, Adappa Nithin D, Palmer James N, O'Malley Bert W, Rassekh Christopher H, Chalian Ara, Cohen Roger B, Lin Alexander: Nodal metastasis and elective nodal level treatment in sinonasal small-cell and sinonasal undifferentiated carcinoma: a surveillance, epidemiology and end results analysis. The British journal of radiology 89 (1058): 20150488,2016.

Sarantopoulos John, Shapiro Geoffrey I, Cohen Roger B, Clark Jeffrey W, Kauh John S, Weiss Glen J, Cleary James M, Mahalingam Devalingam, Pickard Michael D, Faessel Hélène M, Berger Allison J, Burke Kristine, Mulligan George, Dezube Bruce J, Harvey R Donald: Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 22 (4): 847-57,2016.

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.: Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol 26 (6): 1230-7,2015.

Rixe Olivier, Puzanov Igor, LoRusso Patricia M, Cohen Roger B, Morris John C, Olowokure Olugbenga O, Yin Jian Y, Doroumian Séverine, Shen Liji, Olszanski Anthony J: Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-cancer drugs 26 (7): 785-92,2015.

Grover Surbhi, Swisher-McClure Samuel, Mitra Nandita, Li Jiaqi, Cohen Roger B, Ahn Peter H, Lukens John N, Chalian Ara A, Weinstein Gregory S, O'Malley Bert W, Lin Alexander: Total Laryngectomy Versus Larynx Preservation for T4a Larynx Cancer: Patterns of Care and Survival Outcomes. International journal of radiation oncology, biology, physics 92 (3): 594-601,2015.

von Mehren Margaret, Bookman Michael, Meropol Neal J, Weiner Louis M, Sherman Eric, Li Jinhui, Knoblauch Roland, Parekh Trilok, Cohen Roger B: Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer chemotherapy and pharmacology 75 (5): 1047-55,2015.

Chiorean E G, Hurwitz H I, Cohen R B, Schwartz J D, Dalal R P, Fox F E, Gao L, Sweeney C J: Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 26 (6): 1230-7,2015.

Academic Contact Info

Division of Hematology-Oncology
Department of Medicine
University of Pennsylvania School of Medicine

Philadelphia, PA 19104
Phone: (215) 662-4469
Patient appointments: 800-789-PENN (7366)